1 Stock Down 97% That Could Double, According to Wall Street

Core Viewpoint - Investors are shifting away from speculative and unprofitable companies, impacting Editas Medicine, which has seen its shares decline by 97% since early 2021 [1] Company Challenges - Editas Medicine focuses on gene-editing therapies, facing significant challenges in development and marketing [4] - The company's leading program, reni-cel, aimed to treat sickle cell disease and transfusion-dependent beta-thalassemia but was discontinued due to the inability to find a commercial partner [6] - The complexity and high costs associated with ex vivo gene-editing therapies have hindered progress, especially in light of competing therapies that have been approved [5][7] Strategic Shift - Editas Medicine is pivoting towards in vivo gene-editing therapies, which are administered via injection and do not require cell collection [9] - The company has partnered with Bristol Myers Squibb for some of its in vivo programs, indicating a strategic collaboration to enhance its development efforts [9] Financial Outlook - The company has reduced expenses by discontinuing the reni-cel program and laying off a significant portion of its workforce, expecting to maintain a cash balance of $221 million until the second quarter of 2027 [10] - With a current stock price of $1.50, there is potential for the stock to double in value within the next year due to early-stage clinical program progress or potential licensing deals [11] Long-term Viability - Despite potential short-term gains, Editas Medicine is considered too risky for long-term investors, as its current candidates have not yet entered human clinical trials [12] - The company has also abandoned the development of other gene-editing therapies for eye diseases due to similar challenges in finding commercial partners [12][13]